Spots Global Cancer Trial Database for Determining Prognostic Immune Markers in Patients With Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Official Title: Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Study ID: NCT03862677
Conditions
Interventions
Study Description
Brief Summary: The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Detailed Description: Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Leiden University Medical Center, Leiden, , Netherlands
Contact Details
Name: Judith R Kroep, MD PhD
Affiliation: Leiden University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
